Oncotelic Presents Clinical Data of Confirming TGF-?2 as the appropriate target for gliomas at JCA-AACR Meeting 2022
Stock Information for Oncotelic Therapeutics Inc
Loading
Please wait while we load your information from QuoteMedia.
Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.